"Stem cell research is far away and only exists in laboratories." This is the common perception people have of cutting-edge biomedical technologies. However, in Boao Lecheng on the coast of South China's Hainan Province, such technologies are rapidly becoming a reality. From patient treatment to corporate R&D layout, stem cell therapy is no longer a distant "technology of the future".
What exactly is Boao Lecheng International Medical Tourism Pilot Zone? And how far are stem cell technologies from our lives?
“A Special Medical Zone”: The Unique Status of Boao Lecheng
Hainan Boao Lecheng International Medical Tourism Pilot Zone is China's sole "special medical zone". It enjoys “four special policies”, namely special access to medical services, research, operation and international medical exchanges, granting it an unparalleled position in China's medical sector.
In short, Lecheng adopts a pilot-first approach. Global cutting-edge medicines, medical devices and technologies that have not yet been launched nationwide can be applied in clinical practice here first. For innovative fields including cell therapy and gene therapy, Lecheng serves not only as a leading medical treatment hub, but also a transformation bridge connecting the world's latest achievements with domestic clinical demands.
On February 1, 2025, the Regulations on Promoting New Biomedical Technologies in Hainan Free Trade Port Boao Lecheng International Medical Tourism Pilot Zone officially took effect, providing clear legal grounds for the compliant clinical transformation of stem cell and other advanced technologies. This means stem cell research is now carried out in an orderly manner within a sound legal framework.
From Lab to Ward: 29 Technologies Put into Practical Use
Facts speak louder than words. To date, Lecheng has approved 29 cutting-edge biomedical technology projects for clinical transformation and application, covering stem cell therapy, immune cell therapy, gene therapy and more. These technologies are used to treat a variety of intractable diseases such as tumors, neurodegenerative diseases, diabetes, liver cirrhosis and knee osteoarthritis.
At the 3rd Boao Lecheng Stem Cell Conference in March 2026, the fifth batch of cell therapy technologies was released with 6 new projects added:
-
Menstrual blood-derived mesenchymal stem cell therapy for decompensated liver cirrhosis
-
Human umbilical cord mesenchymal stem cell therapy for type 2 diabetes
-
Autologous NK cell therapy combined with immunodrugs for solid tumors
So far, Lecheng has built one of China's most advanced and comprehensive clinical transformation systems for cell and gene therapy. All relevant technologies have completed official price filing, and patients can receive treatment through compliant channels. Stem cell research has truly entered clinical application.
38Fule's Layout in Boao: Bringing Anti-Aging into Reality
On May 13, 2026, 38Fule signed a strategic cooperation agreement with Zhonghai Yinglian in Boao. Leveraging resources including Lecheng's public cell preparation platform and real-world data research institute, the two parties will jointly collect real-world data and conduct clinical transformation research on umbilical cord mesenchymal stem cell therapy for premature ovarian failure.
From May 27 to 28, 38Fule organized the first group of volunteers to visit Boao Lecheng. They toured core medical parks and precision medicine centers, and learned about the R&D process of cell technologies on site. On May 28, the Innovation Center for Cellular Anti-Aging and Regenerative Medicine Technology Research was officially inaugurated in Boao, marking a substantial step forward for 38Fule in the field of cellular anti-aging.
This has consolidated the scientific research foundation for its anti-aging brand BPM. For people concerned about anti-aging, 38Fule is translating cutting-edge stem cell research into accessible products and services. In the future, backed by Lecheng's policy advantages and scientific research platforms, cellular anti-aging technologies will benefit more people.
BPM will continue to delve into cellular anti-aging. Taking regenerative medicine as its core technology, it repairs cells and revitalizes vitality. With precision nutrition as the foundation for health, it maintains basic physical fitness and delivers targeted nutritional support. Committed to repairing cells and delaying aging with sophisticated technologies, BPM also advocates a positive and sustainable healthy lifestyle worldwide. Anti-aging is no longer merely health maintenance, but a wonderful state of life. It empowers every life and makes the world younger.
Boao Lecheng accelerates the transformation of cutting-edge technologies from laboratories to clinical practice via institutional innovation. Up to now, 29 technologies have been launched. Stem cell therapies for diabetes, liver cirrhosis, knee osteoarthritis, premature ovarian failure and other conditions are gradually integrated into clinical practice and daily life.
38Fule's layout in Boao is a microcosm of this health revolution. It proves that the dream of anti-aging is evolving from a question of "whether it can be realized" to "when it will be realized" — and that moment may come much sooner than we expect.